Escherichia coli antibiotic resistance in emergency departments. Do local resistance rates matter?

Eur J Clin Microbiol Infect Dis. 2015 Mar;34(3):571-7. doi: 10.1007/s10096-014-2264-y. Epub 2014 Oct 23.

Abstract

Ciprofloxacin and cotrimoxazole are recommended to treat uncomplicated pyelonephritis and uncomplicated cystitis, respectively, provided that local resistance rates of uropathogens do not exceed specified thresholds (10 and 20 %, respectively). However, Escherichia coli resistance rates in Emergency Departments (ED) remain poorly described. Our objectives were to assess E. coli ciprofloxacin and cotrimoxazole resistance rates in EDs of a French administrative region, and to determine if resistance rates differ between EDs. This was a retrospective study of E. coli urine isolates sampled in ten EDs between 2007 and 2012. The following risk factors for resistance were tested using logistic regression: ED, sex, age, sampling year, sampling month. A total of 17,527 isolates were included. Ciprofloxacin local resistance rates (range, 5.3 % [95 % CI, 4.0-7.1 %] to 11.7 % [95 % CI, 5.2-23.2 %]) were ≤10 % in nine EDs in 2012. Five EDs were risk factors for ciprofloxacin resistance, as were male sex, age and sampling in April or October. Cotrimoxazole local resistance rates (range, 13.3 % [95 % CI, 6.3-25.1 %] to 20.4 % [95 % CI, 18.9-22.0 %]) were ≤20 % in seven EDs in 2012. Five EDs were risk factors for cotrimoxazole resistance, as were age, sampling between October and December, and sampling in 2011 and 2012. We found a significant variability of E. coli ciprofloxacin and cotrimoxazole resistance rates among EDs of a small region. These differences impact on the feasibility of empirical treatment of urinary tract infections with ciprofloxacin or cotrimoxazole in a given ED. Continuous local survey of antibacterial resistance in ED urinary isolates is warranted to guide antibacterial therapy of urinary tract infections.

Publication types

  • Observational Study

MeSH terms

  • Adolescent
  • Aged
  • Aged, 80 and over
  • Anti-Bacterial Agents / pharmacology*
  • Ciprofloxacin / pharmacology*
  • Drug Resistance, Bacterial*
  • Emergency Service, Hospital*
  • Escherichia coli / drug effects*
  • Escherichia coli / isolation & purification
  • Escherichia coli Infections / epidemiology
  • Escherichia coli Infections / microbiology*
  • Female
  • France / epidemiology
  • Humans
  • Male
  • Middle Aged
  • Prevalence
  • Retrospective Studies
  • Risk Factors
  • Trimethoprim, Sulfamethoxazole Drug Combination / pharmacology*
  • Urine / microbiology
  • Young Adult

Substances

  • Anti-Bacterial Agents
  • Ciprofloxacin
  • Trimethoprim, Sulfamethoxazole Drug Combination